![Marcos Quintela-Vazquez AFHEA](https://profiles-cardiff.imgix.net/attachments/6794?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Marcos Quintela-Vazquez
AFHEA
Postdoctoral Research Associate
- Available for postgraduate supervision
School of Biosciences
Overview
I am a postdoctoral researcher based at the European Cancer Stem Cell Research Institute (ECSCRI), currently working with Dr Helen Pearson in a Prostate Cancer UK project investigating a novel treatment against prostate cancer.
My main research interests focus on understanding cancer-associated regulatory networks to identify precise therapeutic strategies and companion diagnostics. During my career, I have engaged with research areas ranging from ovarian/endometrial/prostate cancer, epigenetics, bioinformatics and drug discovery/development.
Publication
2024
- Vaiasicca, S. et al. 2024. Transcriptomic analysis reveals the anti-cancer effect of gestational mesenchymal stem cell secretome. Stem Cells Translational Medicine 13(7), pp. 693-710. (10.1093/stcltm/szae024)
- James, D. W. et al. 2024. Homeobox regulator Wilms Tumour 1 is displaced by androgen receptor at cis-regulatory elements in the endometrium of PCOS patients. Frontiers in Endocrinology 15, article number: 1368494. (10.3389/fendo.2024.1368494)
- Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13(8), article number: 673. (10.3390/cells13080673)
2023
- Vaiasicca, S. et al. 2023. Transcriptomic analysis of stem cells from chorionic villi uncovers the impact of chromosomes 2, 6 and 22 in the clinical manifestations of Down syndrome. Stem Cell Research and Therapy 14(1), article number: 265. (10.1186/s13287-023-03503-4)
- Quintela, M. et al. 2023. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. British Journal of Cancer 129(1), pp. 163–174. (10.1038/s41416-023-02274-2)
- Toubhans, B. et al. 2023. Selenium nanoparticles modulate histone methylation via lysine methyltransferase activity and S-adenosylhomocysteine depletion. Redox Biology 61, article number: 102641. (10.1016/j.redox.2023.102641)
- Quintela, M. et al. 2023. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical Epigenetics 15(1), article number: 63. (10.1186/s13148-023-01477-x)
2022
- Finall, A., James, D., Quintela-Vazquez, M. and Conlan, R. 2022. Differential expression of long non-coding Ribonucleic Acid (RNA) genes in endometriosis-associated ovarian cancer (EAOC): a pilot meta-analysis for pathological insights and potential diagnostic biomarker identification. Journal of Experimental Pathology 3(2), pp. 40-54. (10.33696/pathology.3.039)
- Paradiso, F. et al. 2022. Studying activated fibroblast phenotypes and fibrosis-linked mechanosensing using 3D biomimetic models. Macromolecular Bioscience 22(4), article number: 2100450. (10.1002/mabi.202100450)
- Bauza-Mayol, G. et al. 2022. Biomimetic scaffolds modulate the posttraumatic inflammatory response in articular cartilage contributing to enhanced neoformation of cartilaginous tissue in vivo. Advanced Healthcare Materials 11(1), article number: 2101127. (10.1002/adhm.202101127)
2020
- Friguglietti, J. et al. 2020. Novel silicon titanium diboride micropatterned substrates for cellular patterning. Biomaterials 244, article number: 119927. (10.1016/j.biomaterials.2020.119927)
2019
- Younas, K. et al. 2019. Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11. Journal of Molecular Medicine 97(9), pp. 1315–1327. (10.1007/s00109-019-01809-6)
- Quintela, M. et al. 2019. HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. Nanomedicine: Nanotechnology, Biology and Medicine 17, pp. 254-265. (10.1016/j.nano.2019.01.017)
Articles
- Vaiasicca, S. et al. 2024. Transcriptomic analysis reveals the anti-cancer effect of gestational mesenchymal stem cell secretome. Stem Cells Translational Medicine 13(7), pp. 693-710. (10.1093/stcltm/szae024)
- James, D. W. et al. 2024. Homeobox regulator Wilms Tumour 1 is displaced by androgen receptor at cis-regulatory elements in the endometrium of PCOS patients. Frontiers in Endocrinology 15, article number: 1368494. (10.3389/fendo.2024.1368494)
- Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13(8), article number: 673. (10.3390/cells13080673)
- Vaiasicca, S. et al. 2023. Transcriptomic analysis of stem cells from chorionic villi uncovers the impact of chromosomes 2, 6 and 22 in the clinical manifestations of Down syndrome. Stem Cell Research and Therapy 14(1), article number: 265. (10.1186/s13287-023-03503-4)
- Quintela, M. et al. 2023. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. British Journal of Cancer 129(1), pp. 163–174. (10.1038/s41416-023-02274-2)
- Toubhans, B. et al. 2023. Selenium nanoparticles modulate histone methylation via lysine methyltransferase activity and S-adenosylhomocysteine depletion. Redox Biology 61, article number: 102641. (10.1016/j.redox.2023.102641)
- Quintela, M. et al. 2023. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical Epigenetics 15(1), article number: 63. (10.1186/s13148-023-01477-x)
- Finall, A., James, D., Quintela-Vazquez, M. and Conlan, R. 2022. Differential expression of long non-coding Ribonucleic Acid (RNA) genes in endometriosis-associated ovarian cancer (EAOC): a pilot meta-analysis for pathological insights and potential diagnostic biomarker identification. Journal of Experimental Pathology 3(2), pp. 40-54. (10.33696/pathology.3.039)
- Paradiso, F. et al. 2022. Studying activated fibroblast phenotypes and fibrosis-linked mechanosensing using 3D biomimetic models. Macromolecular Bioscience 22(4), article number: 2100450. (10.1002/mabi.202100450)
- Bauza-Mayol, G. et al. 2022. Biomimetic scaffolds modulate the posttraumatic inflammatory response in articular cartilage contributing to enhanced neoformation of cartilaginous tissue in vivo. Advanced Healthcare Materials 11(1), article number: 2101127. (10.1002/adhm.202101127)
- Friguglietti, J. et al. 2020. Novel silicon titanium diboride micropatterned substrates for cellular patterning. Biomaterials 244, article number: 119927. (10.1016/j.biomaterials.2020.119927)
- Younas, K. et al. 2019. Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11. Journal of Molecular Medicine 97(9), pp. 1315–1327. (10.1007/s00109-019-01809-6)
- Quintela, M. et al. 2019. HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. Nanomedicine: Nanotechnology, Biology and Medicine 17, pp. 254-265. (10.1016/j.nano.2019.01.017)
Teaching
Guest Lecturer (Swansea University)
- MSc. Laboratory measurement techniques for medicinal chemistry and nanomedicine:
- Next-generation sequencing (1h, 2022-2023).
- PCR/qRT-PCR (1h, 2019-2023).
- ELISA, western blot and electrophoresis (1h, 2019-2023).
- MSc. Nanomedicine, Pharmaceuticals and Advanced Therapeutics:
- Targets, actions and receptors (2h, 2019-ongoing).
- BSc. Epigenetics, gene regulation and disease:
- Histone modifications I/II (2h, 2021-2023).
- Gene regulation (1h, 2023).
- Transcription factors (1h, 2023).
Biography
- Research Associate at Cardiff University (current).
- Prostate Cancer UK project led by Dr Helen Pearson.
- Investigating BCL3 as a therapeutic target to treat prostate cancer.
- Research Associate at Swansea University (2019-2023).
- Industrial collaboration with Continuum Life Sciences Ltd. led by Prof Steven Conlan.
- 'Cluster for Epigenomic and Antibody Drug Conjugate Therapeutics' project funded by the European Regional Development Fund via Welsh Government. Industrial collaboration with GlaxoSmithKline and Porvair Sciences Ltd led by Prof Lewis W Francis and Prof Deyarina Gonzalez.
- Data Research Officer at Swansea University (2017-2018).
- PhD in Nanomedicine (2018)
- Joint project between Swansea University and the Houston Methodist Research Institute (2 years).
- The impact of HBO1 in ovarian cancer. Project led by Prof Steven Conlan and Dr Paul Webb.
- MSc in Molecular and Therapeutic Biotechnology at the Autonomous University of Barcelona (1st, 2013).
- BSc in Biotechnology at the University of Salamanca (2:1, 2012).
Speaking engagements
- Invited speaker at the University of A Coruña at the 'Interdisciplinary Centre for Chemistry and Biology (CICA)' and the 'Hospital Materno' site (2023).
- Presentation at the 'Swansea Academy for Learning and Teaching (SALT) Effective Practice Seminar: Researchers who teach, gaining recognition as a post-doctoral researcher'. (2023).
- Online interview for the News Medical Life Sciences portal: Advancing the Diagnosis and Treatment of Ovarian Cancer (2021). Link: https://www.news-medical.net/news/20210407/Advancing-the-Diagnosis-and-Treatment-of-Ovarian-Cancer.aspx
Committees and reviewing
- Volunteer reviewer for Elsevier journals.
- 2 completed reviews in Redox Biology.
- 2 completed reviews in Cancer Reports.
- Early Career Representative on Research Area V (Signaling) committee of the Biochemical Society.
- Member of the scientific committee at the 'Cellular Aging and Metabolism Symposium 2024' (July 2024, A Coruña).
- Member of the Cancer Committee of the Society of Spanish Researchers in the United Kingdom (CERU).
- Member of the Early Career Researchers Commitee at Cardiff University
Supervisions
Past projects
Cardiff University:
- MSc. Investigating the NFkb-BCL3 axis in castration resistant prostate cancer cells (June-Sep 2024).
Swansea University:
- MSc. Investigating the mechanism of action of PLK1 and BRD4 inhibiors in HGSOC (Sep 2022-July 2023).
- BSc. Pharmaceutical manipulation of the SUV39H2-LSD1 regulatory pathway in ovarian cancer (Jan-May 2023).
- BSc. The effect of SUV39H2 inhibitor on the regulation and expression of CYP1A1 and KRT7 (Jan-May 2023).
- BSc. Pharmaceutical manipulation of the lysine-specific demethylase 1 pathway using lysine-specific demethylase 1 inhibitors in ovarian cancer (Jan-May 2023).
- BSc. Investigating the effects of i-BET726 on cisplatin resistance ovarian carcinomas (Jan-May 2022).
- BSc. Investigating the effects of i-BET151 on chemoresistant ovarian carcinomas (Jan-May 2022).
- MSc. Differential expression of long non-coding RNA molecules in endometriosis-related ovarian cancer (Sep 2019- May 2021).
- BSc. Identification of resistant mechanisms and potential re-sensitization strategies in ovarian cancer spheroids (Jan-May 2021).
- BSc. Investigating the epigenetic role of BRD4 in regulating NRG1/HER3 expression in ovarian cancer (Jan-May 2020).
- MSc. Bioinformatic analysis of the role of JMJD3/UTX and H3K27 methylation in ovarian cancer (Sep 2019-May 2020).
- MSc. Epigenetic mechanisms drive potential therapeutic development in gynaecological cancers (Jan 2019-Sep 2020).
Contact Details
Research themes
Specialisms
- Cancer cell biology
- Bioinformatics
- Genomics and transcriptomics
- Translational Drug Discovery
- Cancer therapy